Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2026)

Avalo Therapeutics' Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $25.5 million for Q1 2026.

• Quarterly Cash from Investing Activities changed N/A year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.2 million (changed N/A YoY) and the FY2025 annual result came in at -$81.7 million, down 23055.06% from the prior year.
• Cash from Investing Activities was $25.5 million for Q1 2026 at Avalo Therapeutics, up from $2.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $25.5 million in Q1 2026 and bottomed at -$70.9 million in Q2 2025.
• A 5-year average of -$7.0 million and a median of -$47500.0 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 51.85% — and 2024, when it surged 367.67%.
• Avalo Therapeutics' Cash from Investing Activities stood at -$39000.0 in 2022, then slumped by 241.03% to -$133000.0 in 2023, then jumped by 367.67% to $356000.0 in 2024, then jumped by 574.44% to $2.4 million in 2025, then jumped by 962.27% to $25.5 million in 2026.
• Business Quant data shows AVTX's Cash from Investing Activities at $25.5 million in Q1 2026, $2.4 million in Q4 2025, and -$13.3 million in Q3 2025.